Compare AbbVie Inc (ABBV) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $23.15. The key difference: AbbVie Inc pays a 2.72% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | KOLD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $49.39 |
52-Week Low | $184.85 | $13.58 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
KOLD trades at $23.29, down 0.64% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The stock faces support at $23 and resistance at $24. Recent natural gas market volatility, driven by weather patterns and LNG demand fluctuations, creates trading opportunities for this bearish natural gas ETF.
As a tactical trading instrument, KOLD offers exposure to inverse natural gas price movements amid heightened energy market volatility. Key risks include weather-driven demand shifts and geopolitical factors affecting gas prices, while the bullish technical setup suggests potential near-term upside for this specialized energy sector play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
